Lifecore Biomedical Community

NasdaqGS:LFCR Community

1 Narratives written by author
0 Comments on narratives written by author
1 Fair Values set on narratives written by author

Lifecore Biomedical

AN

AnalystConsensusTarget

Consensus Narrative from 1 Analyst

10 Late-Stage Programs And FDA Approval Will Open Global Opportunities

Key Takeaways Strategic agreements and late-stage pipeline programs are set to drive substantial future revenue growth and improve net margins. Operational efficiencies will enhance net margins by reducing operating expenses, supporting sustainable long-term earnings growth.

US$10.00

FV

36.7% undervalued

12.56%

Revenue growth p.a.

0

0

0

Updated